Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors
Authors:
- 9 April 2013
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (11) , 2433-2440
Abstract
Hematopoietic stem cell and solid organ transplant recipients diagnosed with biopsy-confirmed posttransplant lymphoproliferative disorder (PTLD) at our institution from 1989 to 2010 were identified. Patient-, transplant- and disease-related characteristics, prognostic factors and outcome were collected and analyzed. One hundred and forty biopsy-proven cases of PTLD were included. Overall incidence in the transplant population was 2.12%, with heart transplant recipients carrying the highest risk. Most PTLDs were monomorphic (82%), with diffuse large B-cell lymphoma being the most frequent subtype. The majority of cases (70.7%) occurred > 1 year posttransplant, and 66% were Epstein-Barr virus positive. Following initial therapy the overall response rate was 68.5%. Three-year relapse-free and overall survivals were 59% and 49%, respectively. At last follow-up, 44% of the patients were alive. Multivariable analysis identified several classical lymphoma-specific poor prognostic factors for the different outcome measures. The value of the International Prognostic Index was confirmed in our analysis.Keywords
This publication has 30 references indexed in Scilit:
- Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 casesHaematologica, 2011
- Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★American Journal of Transplantation, 2011
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United StatesAmerican Journal of Hematology, 2010
- Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative DisorderClinical Microbiology Reviews, 2010
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipientsBlood, 2007
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005